This system includes cardiovascular toxicity based on patient baseline characteristics, such as age, hypertension, chronic kidney disease, proteinuria, diabetes, dyslipidemia, history of previous cardiovascular disease (CVD), electrocardiography, TTE assessment (LVEF, LV hypertrophy), and cardiac serum biomarkers including cardiac troponin (cTn) and N-terminal pro-brain natriuretic peptide (NT-proBNP). Here, NPPB is linked to chronic kidney disease.